LNPs or PNPs that is the question

Lipid nanoparticles (LNPs) and polymeric nanoparticles (PNPs) are two leading non-viral drug delivery platforms. While LNPs are the preferred technology for nucleic acid therapeutics, PNPs offer greater versatility for controlled-release and diverse drug delivery applications.

Understanding their key differences is essential for selecting the most appropriate platform for a given therapeutic strategy.

Nanoparticles in modern drug delivery 

Nanoparticle-based delivery systems have become trendy in modern drug development (specially after the pandemic), enabling the effective delivery of cargos that would otherwise suffer from poor stability, limited bioavailability, rapid degradation, or unspecific targeting. By protecting therapeutic agents and improving their pharmacokinetic profiles, nanocarriers have expanded the range of drug candidates that can successfully reach clinical development.

Among the available technologies, lipid nanoparticles (LNPs) and polymeric nanoparticles (PNPs) have emerged as two of the most widely studied and commercially relevant platforms. Although both systems aim to enhance therapeutic delivery, they differ significantly in their composition, biological behavior, manufacturing strategies, and clinical applications. The recent success of LNP-enabled mRNA vaccines and siRNA therapeutics has highlighted the potential of lipid-based delivery systems for nucleic acid medicines, while PNPs continue to attract interest due to their versatility, controlled-release capabilities, and compatibility with a broad range of payloads, including small molecules, proteins, peptides, and biologics.

Understanding the key differences between LNPs and PNPs is therefore essential for developers seeking to identify the most appropriate delivery system and accelerate the development of safe, effective, and scalable therapeutics.

1. Composition

The composition of a nanoparticle directly influences its stability, biodistribution, encapsulation efficiency, and manufacturability. While both LNPs and PNPs can be engineered for specific applications, they differ fundamentally in the materials used to form the nanoparticle structure.

LNPs are built from a relatively standardized combination of lipid excipients. Each lipid class performs a specific function within the particle, resulting in a highly organized delivery system optimized for nucleic acid transport.

PNPs, by contrast, rely on one or more polymeric materials that form the structural matrix of the nanoparticle. Rather than depending on a fixed composition, their properties are largely dictated by polymer selection, allowing extensive customization of degradation rates, release kinetics, and targeting capabilities.

Ultimately, the composition of a nanoparticle dictates how it behaves in vivo and which therapeutic challenges it can address. While the lipid architecture of LNPs is highly optimized for nucleic acid delivery, the broader material diversity of PNPs provides greater opportunities to engineer degradation, drug release, and targeting properties, enabling a wider range of delivery strategies.

2. Payload Delivery and Versatility 

The therapeutic cargo is often a key factor determining the most suitable nanoparticle platform. Both lipid nanoparticles (LNPs) and polymeric nanoparticles (PNPs) can protect therapeutic payloads, improve biodistribution, and facilitate cellular delivery, but their formulation principles make them suitable for different types of cargo.

LNPs have become a leading platform for the delivery of mRNA, siRNA, and other nucleic acid therapeutics, as ionizable lipids efficiently associate with negatively charged nucleic acids and facilitate cellular uptake and endosomal escape. Their established performance makes them particularly attractive for systemic RNA delivery.

Within PNPs, it is important to distinguish between electrostatically assembled systems, such as polyplexes, and matrix-based systems, such as PLGA nanoparticles. Cationic or ionizable polymers can complex negatively charged nucleic acids, protecting them from degradation while promoting efficient intracellular trafficking and, when appropriately engineered, nuclear delivery. Leveraging these advantages, Curapath’s proprietary STAR-CXP polymer platform has been specifically developed to maximize nucleic acid delivery performance by enhancing cellular uptake, endosomal escape, and nuclear localization, making it particularly well suited for DNA-based therapeutics and other applications requiring efficient intracellular transport.

In contrast, matrix-based PNPs such as PLGA incorporate the cargo within a biodegradable polymeric matrix, with release governed mainly by diffusion and polymer degradation or erosion. This makes them particularly suitable for controlled and sustained delivery of small molecules, peptides, proteins, and, with appropriate formulation strategies, nucleic acids.

Thus, electrostatically assembled PNPs are particularly suited to nucleic acid and nuclear delivery, whereas matrix-based systems such as PLGA are especially valuable for controlled and sustained release of diverse therapeutic cargos. LNPs and these distinct PNP architectures therefore offer complementary approaches that can be tailored to the therapeutic cargo and desired site of action.

3. Regulatory Pathway 

Regulatory considerations can significantly impact development timelines and commercialization strategies. Although both LNPs and PNPs are regulated under established pharmaceutical frameworks, developers must demonstrate thorough characterization and control of critical nanoparticle attributes to ensure product safety, efficacy, and manufacturing consistency.

LNPs: A More Established Regulatory Framework

Among non-viral delivery systems, LNPs currently have a most mature regulatory pathway. The approval of multiple siRNA therapeutics and mRNA vaccines has created a growing body of regulatory precedent, particularly regarding characterization methods, critical quality attributes (CQAs), manufacturing controls, and stability requirements.

Consistent with FDA Chemistry, Manufacturing and Controls (CMC) guidance, release specifications for LNPs should include characterization of critical quality attributes (CQAs), such as:

• Particle size and size distribution
• Polydispersity index (PDI)
• Zeta potential (where relevant)
• Encapsulation efficiency (encapsulated vs. free therapeutic)
• Lipid composition and lipid content
• Identity and assay of the active ingredient
• Impurity and degradation product profile
• In vitro release profile (where applicable)
• Residual organic solvents
• pH and osmolality (for parenteral formulations)
• Sterility
• Bacterial endotoxins
• Visual appearance (e.g., absence of visible particulates)

Because LNPs have evolved into a relatively well-established delivery platform, developers can leverage accumulated regulatory experience, established characterization approaches, and existing precedents when designing development programs, particularly for formulations based on commonly used lipid components.

Novel Lipid Excipients and CMC Challenges

Despite increased regulatory familiarity, LNP development is not without challenges. One important consideration is the increasingly crowded intellectual property (IP) landscape, particularly around proprietary ionizable lipids and novel excipients, which can limit freedom to operate and complicate the development of new LNP formulations.

From a Chemistry, Manufacturing and Controls (CMC) perspective, regulatory authorities often require extensive data packages demonstrating:

• Impurity profiles
• Lipid degradation pathways
• Batch consistency
• Excipient-related toxicology
• Long-term stability

The use of novel lipid excipients may therefore introduce additional regulatory risk, particularly when limited human safety data are available. Early engagement with regulatory agencies is often recommended to align on characterization strategies and acceptable control plans.

PNPs: Greater Flexibility, Higher Regulatory Complexity

For PNPs, the regulatory landscape is generally less standardized. Unlike LNPs, where composition often follows a common formulation paradigm, polymeric systems can be constructed from a wide variety of natural, semi-synthetic, or synthetic polymers, creating substantially greater product diversity. This flexibility expands the design space but also increases regulatory complexity, particularly for novel polymers for which limited regulatory precedent and publicly available regulatory experience are available.

Well-established polymers used in matrix-based nanoparticles, such as PLGA and PLA, benefit from extensive historical use and established safety data, with some polymeric excipients having regulatory recognition or GRAS status for specific applications. However, this established safety profile does not automatically extend to the final nanoparticle formulation, which must still be characterized and evaluated as a drug product.

For polycationic or ionizable polymers used for nucleic acid delivery, the regulatory considerations are different. These materials are often less established as pharmaceutical excipients and may require additional characterization and safety studies, including:

• Biocompatibility
• Biodegradation and biological fate
• Metabolite and degradation-product safety
• Immunogenicity risk
• Potential tissue accumulation
• Long-term toxicological profile

Regulatory assessment may therefore place particular emphasis on the polymer itself, its degradation products, and their biological fate, especially for novel polymer chemistries.

Key Quality Attributes for LNPs and PNPs

For both LNPs and PNPs, regulatory assessment focuses on the physicochemical properties, cargo quality, manufacturing consistency, and biological performance of the final nanoparticle product. However, each platform presents specific attributes that require particular attention.

This separation is cleaner because the common nanoparticle CQAs are retained, while the platform-specific differences are highlighted: LNPs require particular attention to lipid composition, whereas PNPs require characterization of polymer properties and nucleic acid complexation.

Overall, LNPs benefit from a more established regulatory pathway, while PNPs generally require a more case-by-case assessment due to greater material and formulation diversity.

4. Scale-Up and Technology Transfer 

An effective nanoparticle formulation must not only perform well in the laboratory but also be reliably manufactured at commercial scale. Therefore, scale-up, process control, and technology transfer are critical considerations for both LNPs and PNPs.

For LNPs, microfluidic and other controlled mixing technologies have enabled more reproducible nanoparticle production. Process parameters such as flow rates, mixing conditions, lipid composition, and concentration can influence key attributes including particle size, PDI, encapsulation efficiency, and payload integrity. However, maintaining consistency during scale-up remains challenging due to the multicomponent and highly process-dependent nature of LNP formulations.

For PNPs, scalability also depends strongly on formulation and process conditions. Parameters such as polymer concentration, solvent system, mixing conditions, and particle formation kinetics can substantially affect the final nanoparticle properties. Thus, robust process control and reproducible manufacturing are essential for successful scale-up and technology transfer.

Common Manufacturing Challenges During Scale-Up

As production moves from laboratory scale to commercial manufacturing, maintaining consistency often requires significant process optimization and extensive analytical control. Consequently, PNP-based products may face a more challenging technology transfer process than LNP-based systems.

5. Choosing Between LNPs and PNPs

There is no universal nanoparticle platform suitable for every application. The optimal choice depends on how the properties of the delivery system align with the therapeutic objective, the payload, and the intended product profile.

LNPs have established a strong position in nucleic acid delivery, particularly for RNA therapeutics, supported by high delivery efficiency and increasing clinical and regulatory experience. PNPs, however, offer a broader design space, with the possibility to tailor polymer chemistry, charge, degradation, release kinetics, and surface functionality. This versatility makes them attractive not only for small molecules, peptides, and proteins, but also for DNA and other nucleic acid-based therapeutics.

Ultimately, the decision between LNPs and PNPs should not be based on the payload alone. Intracellular delivery requirements, release profile, stability, route of administration, targeting strategy, manufacturability, scalability, and regulatory considerations can all influence which platform is best suited for a specific program.

In many cases, the question is therefore not simply “LNP or PNP?”, but rather which nanoparticle architecture provides the right combination of protection, delivery, release, and manufacturability for the therapeutic goal.

At Curapath, we work across both lipid- and polymer-based drug delivery platforms, supporting projects from early formulation and process development through scale-up and GMP manufacturing. This platform-agnostic approach allows us to focus on selecting and developing the delivery system that best fits each therapeutic program.

Need help identifying the right nanoparticle platform for your payload? Get in touch with our team and let’s explore the best path forward.